4.5 Article

Management of physical health in schizophrenia: A stepping stone to treatment success

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 18, 期 -, 页码 S121-S128

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2008.02.002

关键词

diabetes; metabolic syndrome; atypical antipsychotics

向作者/读者索取更多资源

White patients with schizophrenia are known to have an increased risk of physical health comorbidity including coronary heart disease, diabetes, hypertension, stroke and emphysema, their physical wellbeing often goes unnoticed by health care professionals. In many cases the patient's only contact with the health service is through the mental health team. However, many psychiatrists consider their primary function to be the provision of clinical care in terms of symptom control and are reluctant to switch medication despite the presence of physical health issues. Nevertheless outcomes in schizophrenia may be improved by expanding the remit of the clinician to include assessments of both physical and mental health. Simple measurements such as waist circumference, weight, height, blood pressure and blood sampling would provide the psychiatrist with useful information that could be used to optimize treatment and improve overall quality of life for patients with schizophrenia. (c) 2008 Elsevier B.V. and ECNP. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Clinical Neurology

A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS

Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns

Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2024)